Core Insights - The company reported third-quarter revenue of 5.564 billion, representing a year-on-year increase of 1.97% [1] - The net profit for the third quarter was 345 million, showing a year-on-year growth of 10.14% [1] - For the first three quarters, the total revenue reached 17.286 billion, with a year-on-year increase of 0.39% [1] - The net profit for the first three quarters was 1.225 billion, reflecting a year-on-year growth of 10.27% [1] Financial Performance - Third-quarter revenue: 5.564 billion, up 1.97% year-on-year [1] - Third-quarter net profit: 345 million, up 10.14% year-on-year [1] - Year-to-date revenue (first three quarters): 17.286 billion, up 0.39% year-on-year [1] - Year-to-date net profit (first three quarters): 1.225 billion, up 10.27% year-on-year [1]

益丰大药房作为全国大型药品零售连锁企业，始终秉持着"用心关爱每一位顾客"的理念，通过专业药事 服务和高品质产品，为大众健康提供坚实保障。此次与欧姆龙的携手合作，是双方共同推动全民健康管 理的一次积极实践。 本次"心动钜惠节"推出血压计、雾化器等健康设备的特惠促销活动，让市民能够用以更实惠的价格购买 到优质的健康产品。这一举措不仅降低了家庭健康管理门槛，也体现了欧姆龙将"守护国民健康"落到实 处的匠心与温度。 欧姆龙始终秉持"Going for ZERO，预防医疗，让世界更健康"的美好愿景，致力于将专业的医疗器械产 品变得易用、可靠、贴近生活。未来，欧姆龙将持续推动全民健康管理理念的普及，把科学、便捷的健 康守护延伸至更多城市和社区，让每一个家庭都能享受到专业、可信赖的健康关怀。 上海2025年10月29日 /美通社/ -- 10月29日，正值重阳佳节，同时也是第20届"世界卒中日"。在这一全球 健康倡导日，欧姆龙健康医疗（中国）有限公司携手上海益丰药房，推出以"测压省心 智享安心"为主 题的"心动钜惠节"活动。本次活动旨在普惠市民，让更多人可以享有高品质的健康产品与专业服务，同 时进一步提升全民对脑卒中防控的 ...

| 证券代码：603939 | 证券简称：益丰药房 | 公告编号：2025-102 | | --- | --- | --- | | 债券代码：113682 | 债券简称：益丰转债 | | 益丰大药房连锁股份有限公司 关于募集资金委托理财进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次赎回产品基本情况 | 产品名称 | 利多多公司稳利 期 25JG3300 | | | --- | --- | --- | | 受托方名称 | 上海浦东发展银行股份有限公司 | | | 购买金额 | 6,400.00 | 万元 | | 产品期限 | 天 89 | | | 产品名称 | 2025 | 年第 | 851 | 期公司结构性存款 | | --- | --- | --- | --- | --- | | 受托方名称 | | | 长沙银行股份有限公司 | | | 购买金额 | 2,125.00 | | 万元 | | | 产品期限 | 天 90 | | | | | 产品名称 | 2025 | 年第 | 852 | 期公 ...

Core Viewpoint - On October 27, a total of 10 listed companies had their restricted shares unlocked, with a total market value of approximately 18.54 billion yuan [1] Summary by Category Restricted Share Unlocking - Xiamen Bank (601187) extended the lock-up period for 1.348 billion shares [1] - Guangzheng Eye Hospital (002524) released 2.2245 million shares under equity incentive restrictions [1] - Shapuaisi (603168) released 30,000 shares under equity incentive restrictions [1] - Yifeng Pharmacy (603939) released 195,000 shares under equity incentive restrictions [1] - Jihong Co., Ltd. (002803) released 1.98 million shares under equity incentive restrictions [1] - Mingyang Circuit (300739) released 1.2387 million shares under equity incentive restrictions [1] - Arrow Home (001322) released 800 million shares under pre-issue restrictions [1] - Ruichen Environmental Protection (301273) released 3.70125 million shares under pre-issue restrictions [1] - Jinchengzi (688291) released 6.9 million shares [1] - Weice Technology (688372) released 2.70328 million shares [1]

Core Points - The company has provided a guarantee for its wholly-owned subsidiary, Jiangsu Yifeng, to support its application for comprehensive credit from financial institutions [2][3] - The total amount of the guarantee provided by the company does not exceed 3.09 billion yuan, which is within the approved limit from the annual shareholders' meeting [3][5] - The guarantee is intended to meet the operational and business development funding needs of the company and its subsidiary, ensuring smooth business operations [5] Summary by Sections Guarantee Details - The company signed a maximum guarantee contract with financial institutions in September 2025, providing joint liability guarantees for Jiangsu Yifeng's credit application [2] - The specific guarantee amount is 250 million yuan, covering various financial obligations including principal, interest, penalties, and related costs [3] Internal Decision-Making Process - The board of directors approved the guarantee proposal during meetings held on April 28, 2025, and May 29, 2025 [3] Financial Health of the Subsidiary - Jiangsu Yifeng is described as having good profitability and the ability to repay debts, with financial risks being manageable within the company [5] Board's Opinion - The board believes that providing the guarantee is a reasonable estimate based on business development needs and financial capabilities, aligning with the company's overall strategic goals [5] Cumulative Guarantee Situation - As of the announcement date, the total external guarantees provided by the company and its subsidiaries amount to 3.315 billion yuan, representing 30.91% of the latest audited net assets [5]

| 证券代码：603939 | 证券简称：益丰药房 | 公告编号：2025-101 | | --- | --- | --- | | 债券代码：113682 | 债券简称：益丰转债 | | 益丰大药房连锁股份有限公司 关于为控股子公司提供担保的进展公告 担保对象及基本情况 累计担保情况 | 对外担保逾期的累计金额（万元） | 0 | | --- | --- | | 截至本公告日上市公司及其控股 | 331,500（含本次担保） | | 子公司对外担保总额（万元） | | | 对外担保总额占上市公司最近一 | 30.91% | | 期经审计净资产的比例（%） | | | 特别风险提示（如有请勾选） | □对外担保总额（含本次）超过上市公司最 | | | 近一期经审计净资产 50% | | | □对外担保总额（含本次）超过上市公司最 | | | 近一期经审计净资产 100% | | | □对合并报表外单位担保总额（含本次）达 | | | 到或超过最近一期经审计净资产 30% | | | □本次对资产负债率超过 70%的单位提供担 | | 保 | | | 其他风险提示（如有） | / | 一、担保情况概述 （一）担保 ...

Market Overview - The pharmaceutical commercial sector increased by 0.44% on October 23, with Jianfa Zhixin leading the gains [1] - The Shanghai Composite Index closed at 3922.41, up 0.22%, while the Shenzhen Component Index closed at 13025.45, also up 0.22% [1] Stock Performance - Jianfa Zhixin (301584) saw a significant rise of 20.00%, closing at 37.20 with a trading volume of 301,100 shares and a transaction value of 1.046 billion [1] - Other notable performers included: - Kaikai Industrial (600272) up 2.20% to 13.49 [1] - First Pharmaceutical (600833) up 1.97% to 14.01 [1] - Dazhenlin (603233) up 1.48% to 19.20 [1] - Yifeng Pharmacy (603939) up 1.31% to 25.44 [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 97.0483 million from institutional investors and 117 million from speculative funds, while retail investors saw a net inflow of 214 million [2] - The capital flow for key stocks showed: - Jianfa Zhixin had a net inflow of 1.22 billion from institutional investors, but a net outflow of 58.2871 million from speculative funds [3] - Kaikai Industrial had a net inflow of 15.4487 million from institutional investors, with a net outflow of 3.9622 million from speculative funds [3]

Core Insights - Yifeng Pharmacy's stock price remained unchanged on October 22, with a trading volume of 129 million yuan, indicating stable market activity [1] - The company reported a financing net purchase of 980,700 yuan on the same day, reflecting a low financing balance compared to historical levels [1] - For the first half of 2025, Yifeng Pharmacy achieved a revenue of 11.722 billion yuan, a slight decrease of 0.35% year-on-year, while net profit increased by 10.32% to 880 million yuan [2] Financing and Margin Trading - On October 22, Yifeng Pharmacy had a financing buy amount of 9.0041 million yuan and a financing repayment of 8.0234 million yuan, resulting in a net financing purchase of 980,700 yuan [1] - The total financing and margin trading balance as of October 22 was 98.1041 million yuan, with the financing balance at 93.2032 million yuan, representing 0.31% of the circulating market value [1] - The company’s financing balance is currently below the 40th percentile of the past year, indicating a low level of leverage [1] Shareholder and Dividend Information - As of June 30, the number of shareholders increased by 7.70% to 21,600, while the average circulating shares per person decreased by 7.15% to 56,081 shares [2] - Since its A-share listing, Yifeng Pharmacy has distributed a total of 2.852 billion yuan in dividends, with 1.946 billion yuan distributed in the last three years [3] - The second-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 237 million shares, a decrease of 35.3896 million shares from the previous period [3]

Core Insights - The pharmaceutical commercial sector saw an increase of 0.83% on October 22, with Jianfa Zhixin leading the gains [1] - The Shanghai Composite Index closed at 3913.76, down 0.07%, while the Shenzhen Component Index closed at 12996.61, down 0.62% [1] Stock Performance - Jianfa Zhixin (301584) closed at 31.00, up 7.19% with a trading volume of 238,100 shares and a transaction value of 734 million [1] - Guoyao Shares (600511) closed at 29.89, up 3.75% with a trading volume of 180,500 shares and a transaction value of 539 million [1] - Zhejiang Nongyuan (000705) closed at 9.81, up 3.05% with a trading volume of 117,170 shares and a transaction value of 168 million [1] - Other notable stocks include Jiashitang (002462) up 1.51%, Daclin (603233) up 1.34%, and Guofa Shares (600538) up 1.20% [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 98.42 million from institutional investors and 51.45 million from retail investors, while individual investors saw a net inflow of 150 million [2] - The capital flow for key stocks shows varying trends, with Shanghai Pharmaceuticals (601607) seeing a net inflow of 31.94 million from institutional investors [3] - Jianfa Zhixin (301584) had a net inflow of 18.64 million from institutional investors but a net outflow of 2.07 million from retail investors [3]

Core Points - The announcement pertains to the second unlock and listing of restricted stock under the 2022 Restricted Stock Incentive Plan of Yifeng Pharmacy Chain Co., Ltd [1][2] Group 1: Stock Incentive Plan Overview - The stock type being listed is for equity incentive shares, with a total of 196,838 shares available for trading [2] - The listing date for these shares is set for October 27, 2025 [2] Group 2: Implementation of the Incentive Plan - The incentive plan was approved during the board and supervisory meetings held on August 19, 2022, with independent opinions provided by independent directors [3] - The names and positions of the incentive recipients were publicly disclosed from August 20 to August 29, 2022, with no objections received [3][4] - The plan was further approved at the third extraordinary general meeting of shareholders on September 5, 2022 [4] Group 3: Unlocking Conditions and History - The first unlock of 216,668 shares was approved on October 14, 2024, for 32 recipients [4][5] - The second unlock of 196,838 shares was approved on September 30, 2025, for 29 recipients [5] Group 4: Legal Compliance and Conclusion - The law firm Hunan Qiyuan concluded that the conditions for the unlock and listing have been met, and all necessary approval procedures have been followed [7]